The group's principal activity is to conduct research, develop and market biological products for the treatment and control of cancer. The main product provided by the group is canvaxin, which is one of a new class of products being developed in the area of specific active immunotherapy, also known as therapeutic cancer vaccines. The group became publicly held on 04- nov-2003.
